Matthew Gall
2023
In 2023, Matthew Gall earned a total compensation of $2.7M as Chief Financial Officer at iTeos Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $191,851 |
|---|---|
| Option Awards | $1,664,000 |
| Salary | $441,150 |
| Stock Awards | $403,440 |
| Other | $15,000 |
| Total | $2,715,441 |
Gall received $1.7M in option awards, accounting for 61% of the total pay in 2023.
Gall also received $191.9K in non-equity incentive plan, $441.2K in salary, $403.4K in stock awards and $15K in other compensation.
Rankings
In 2023, Matthew Gall's compensation ranked 345th out of 2,910 executives tracked by ExecPay. In other words, Gall earned more than 88.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 345 out of 2,910 | 88th |
Division Manufacturing | 198 out of 1,602 | 88th |
Major group Chemicals And Allied Products | 136 out of 901 | 85th |
Industry group Drugs | 133 out of 864 | 85th |
Industry Biological Products, Except Diagnostic Substances | 47 out of 211 | 78th |
Source: SEC filing on April 25, 2024.
Gall's colleagues
We found two more compensation records of executives who worked with Matthew Gall at iTeos Therapeutics in 2023.